Results 151 to 160 of about 141,357 (291)

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo   +11 more
wiley   +1 more source

Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations

open access: yesInternational Journal of Dermatology, EarlyView.
A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair   +17 more
wiley   +1 more source

CH50 as a Clinically Useful Biomarker of Disease Activity and Antihistamine Resistance in Chronic Spontaneous Urticaria: An Observational Ambispective Single‐Center Study

open access: yesInternational Journal of Dermatology, EarlyView.
Personalized CSU care guided by CH50. ABSTRACT Background Chronic spontaneous urticaria (CSU) is frequently refractory to guideline‐based therapy, highlighting the need for predictive biomarkers. Dysregulation of the complement system has been implicated in CSU severity, but global complement activity has not been systematically evaluated.
Nidia Planella‐Fontanillas   +9 more
wiley   +1 more source

Bile diversion and cyclosporine dosage (Letter) [PDF]

open access: yes, 1985
Andrews, W   +3 more
core  

Contempo 90: Transplantation [PDF]

open access: yes, 1990
Fung, JJ, Starzl, TE
core  

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy